(Q54645380)

2 June 2018

title

High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. (English)

1 reference

2 June 2018

author

Werner J. Heinz

1

1 reference

2 June 2018

author name string

Kathrin Kahle

2

1 reference

2 June 2018

Annegret Helle-Beyersdorf

3

1 reference

2 June 2018

Diana Schirmer

4

1 reference

2 June 2018

Ulrike Lenker

5

1 reference

2 June 2018

Daniela Keller

6

1 reference

2 June 2018

Peter Langmann

7

1 reference

2 June 2018

Hartwig Klinker

8

1 reference

2 June 2018

publication date

7 October 2010

1 reference

2 June 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

2 June 2018

volume

68

1 reference

2 June 2018

issue

1

1 reference

2 June 2018

page(s)

239-245

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s00280-010-1474-y

exact match

0 references

cites work

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Setting system suitability criteria for detectability in high-performance liquid chromatography methods using signal-to-noise ratio statistical tolerance intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Validation of bioanalytical chromatographic methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1474-Y

10.1007/S00280-010-1474-Y

21 January 2018

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018